Welcome to our dedicated page for Lisata Therapeutics SEC filings (Ticker: LSTA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Lisata Therapeutics, Inc. (LSTA) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Lisata is a clinical-stage pharmaceutical company focused on certepetide, an investigational internalizing RGD cyclic peptide being developed for advanced solid tumors and other serious diseases. Its filings help investors understand how clinical progress, licensing agreements and intellectual property developments are reflected in formal reports.
Recent Form 8-K filings from Lisata have covered topics such as quarterly financial results, preliminary clinical data from the ASCEND trial in metastatic pancreatic ductal adenocarcinoma, corporate presentations used at investor and industry conferences, a new composition of matter patent for certepetide and a worldwide non-exclusive license agreement with Catalent, Inc. for use of certepetide as a SMARTag® antibody-drug conjugate payload. These current reports provide timely detail on material events, including business development milestones and updates to the company’s cash runway expectations.
Through this page, users can track Lisata’s ongoing 8-K disclosures and, as they are filed, review annual reports on Form 10-K, quarterly reports on Form 10-Q, and other materials that describe the company’s clinical programs, risk factors, intellectual property, and financial condition. Stock Titan enhances this information with AI-powered summaries that highlight key points from lengthy documents, helping readers quickly identify items such as new trial data descriptions, changes in development strategy, or licensing and patent developments related to certepetide.
For those following LSTA, this filings archive offers a structured view of Lisata’s regulatory history, from clinical and business updates reported on Form 8-K to broader periodic reports that outline the company’s operations and oncology-focused development plans.
Lisata Therapeutics President & CEO David J. Mazzo reported new equity awards and related tax withholdings. On January 9, 2026, he received 81,000 shares of restricted stock under the company’s 2018 Equity Incentive Compensation Plan at a stated price of $0. These restricted shares vest in four equal installments, starting on the grant date and then on each of the first three anniversaries.
On the same date, he was granted a stock option for 40,000 shares of common stock with an exercise price of $1.97 per share, also vesting in four equal annual installments beginning on the grant date. To cover tax liabilities from vesting restricted stock, a total of 41,096 shares of common stock were withheld at $1.97 per share. After these transactions, Mazzo directly beneficially owned 311,890 shares of common stock, including 124,750 unvested restricted shares.
Lisata Therapeutics, Inc. reported equity awards and related tax withholdings for senior executive James Nisco, SVP Finance, Treasurer and Chief Accounting Officer. On January 9, 2026, he received 15,000 shares of restricted common stock at a price of $0 under the company’s 2018 Equity Incentive Compensation Plan. These restricted shares vest in four equal parts, with one quarter vesting on the grant date and additional quarters vesting on each of the first, second and third anniversaries of the grant.
The filing also shows tax-related share withholdings: blocks of 2,131, 2,131, 1,137 and 781 common shares were withheld at $1.97 per share to cover taxes upon vesting of restricted stock. After these transactions, Nisco directly held 32,311 shares of common stock, which include 20,750 unvested restricted shares.
In addition, Nisco was granted a stock option for 7,000 shares of common stock at an exercise price of $1.97 per share. One quarter of the option vested on the grant date, with further quarters scheduled to vest on the first, second and third anniversaries of January 9, 2026, and the option expires on January 9, 2036.
Lisata Therapeutics, Inc. executive Tariq Imam, SVP Business Development and General Counsel, reported new equity awards and related tax withholdings. On January 9, 2026, he received 15,000 shares of common stock as restricted stock awards under the company’s 2018 Equity Incentive Compensation Plan at a price of $0. These restricted shares vest in four equal parts: one-quarter on the grant date and one-quarter on each of the first three anniversaries.
After this grant, he directly owned 39,579 shares of common stock, including 17,750 unvested restricted shares. Several transactions coded "F" show a total of 1,401, 840, 747 and 513 shares of common stock withheld at $1.97 per share to cover tax liabilities from restricted stock vesting, leaving 36,078 common shares directly owned. Imam was also granted a stock option for 7,000 shares at an exercise price of $1.97 per share, with one-quarter vesting immediately on January 9, 2026 and the remainder vesting in three annual installments through an expiration date of January 9, 2036.
Lisata Therapeutics executive Kristen K. Buck, EVP, R&D and CMO, reported new equity awards and related tax-withholding transactions. On 01/09/2026 she received 25,000 shares of common stock as restricted stock awards under Lisata’s 2018 Equity Incentive Compensation Plan, vesting in four equal annual installments starting on the grant date. On the same date she was also granted stock options for 13,000 shares at an exercise price of
To cover tax liabilities from vesting restricted stock, multiple transactions coded “F” withheld a total of 11,332 common shares at
Lisata Therapeutics, Inc. director Steven M. Klosk received an equity award of 30,456 shares of common stock in the form of restricted stock units. The grant was made on January 9, 2026 under the company’s 2018 Equity Incentive Compensation Plan at a price of $0 per share, reflecting a compensatory award rather than a purchase.
The 30,456 restricted stock units will vest on January 9, 2027. After this grant, Klosk beneficially owns a total of 95,815 shares of common stock, which includes the 30,456 unvested restricted stock units reported in this filing, all held as direct ownership.
Lisata Therapeutics director Heidi Henson reported a new equity award. On January 9, 2026 she received 30,456 shares of common stock in the form of restricted stock units granted under Lisata’s 2018 Equity Incentive Compensation Plan at a grant price of $0 per share.
The restricted stock units are scheduled to vest on January 9, 2027, meaning the shares will become fully owned at that time if vesting conditions are met. After this grant, Henson beneficially owns 85,725 shares of Lisata common stock, which includes 30,456 unvested restricted stock units. The filing characterizes her ownership as direct.
Lisata Therapeutics director Cynthia Louise Flowers reported an equity grant from the company. On January 9, 2026, she was awarded 30,456 shares of common stock in the form of restricted stock units under Lisata’s 2018 Equity Incentive Compensation Plan at a grant price of $0 per share.
These 30,456 restricted stock units are scheduled to vest on January 9, 2027. After this grant, Flowers beneficially owns 95,446 shares of Lisata common stock, which includes the 30,456 unvested restricted stock units.
Lisata Therapeutics director Gregory B. Brown reported receiving 30,456 restricted stock units of common stock on January 9, 2026 under the company’s 2018 Equity Incentive Compensation Plan. These restricted stock units are scheduled to vest on January 9, 2027. Following this grant, he beneficially owns 95,659 shares of Lisata Therapeutics common stock, including 30,456 unvested restricted stock units.
Lisata Therapeutics director granted restricted stock units
Lisata Therapeutics, Inc. director Mohammad Azab reported an award of 30,456 shares of common stock on January 9, 2026. The filing states these are restricted stock units granted under the company’s 2018 Equity Incentive Compensation Plan and that they will vest on January 9, 2027. The units were recorded at a price of $0 per share, reflecting that this was an equity grant rather than an open-market purchase.
After this grant, Azab is reported to beneficially own 104,925 shares of common stock, which the disclosure notes includes 30,456 unvested restricted stock units. The ownership is reported as held directly.
Lisata Therapeutics (LSTA) filed its Q3 2025 10‑Q, reporting a quarterly net loss of $4.249 million as operating expenses declined to $4.414 million from $5.336 million a year ago. Revenue was $0 in the quarter and $70 thousand year‑to‑date.
Liquidity and balance sheet: Cash and cash equivalents were $18.998 million, with total assets of $21.759 million and stockholders’ equity of $17.373 million as of September 30, 2025. The company states it has sufficient cash to meet funding requirements over the next 12 months and expects to seek additional financing by the end of 2026.
Operations and expenses: R&D was $1.959 million and G&A was $2.455 million in Q3. Year‑to‑date, R&D totaled $6.815 million and G&A $8.385 million. The company continued Phase 2 studies of certepetide and delayed certain Phase 3 readiness activities to manage cash.
Capital actions: Lisata raised $600,663 in net proceeds via its ATM during the nine months ended September 30, 2025 and sold $10.7 million of New Jersey NOLs for net proceeds of $871 thousand, recording a $962 thousand deferred income tax benefit.
FAQ
What is the current stock price of Lisata Therapeutics (LSTA)?
What is the market cap of Lisata Therapeutics (LSTA)?
